Cellebrite DI Ltd.

Cellebrite DI Ltd.

CLBT
Cellebrite DI Ltd.US flagNASDAQ Global Select
11.94
USD
+0.32
- -
2.98BMarket Cap
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.92
1.04
1.71
1.48
1.71
1.92
1.97
2.04
Basic EPS, GAAP
-0.05
-0.05
0.5
0.66
-0.43
-1.35
0.32
0.29
Free Cash Flow per Basic Share
0.05
0.32
0.19
0.06
0.5
0.58
0.66
0.62
Dividend per Share
0.13
0.05
0.69
- -
- -
- -
- -
- -
Book Value per Share
0.31
0.34
-0.39
0.38
0.17
1.43
1.95
2.05
Tangible Book Value per Share
0.31
0.26
-0.59
0.19
-0.02
1.26
1.14
1.05
Basic Weighted Avg Shares
187
187
144
183
190
209
242
244
Sales/Revenue/Turnover
172
195
246
271
325
401
476
496
Operating Margin (%)
-0.88
4.73
5.61
0.39
10.22
14.18
13.98
12.76
Depreciation Expense
4
6
7
9
10
11
12
16
Net Income, GAAP
-2
6
71
121
-81
-283
78
72
Effective Tax Rate (%)
232.58
49.28
13.25
- -
- -
- -
13.62
15.44
Profit Margin (%)
-1.09
2.97
28.99
44.63
-24.95
-70.54
16.47
14.48
Working Capital
163
165
87
88
168
272
206
191
LT Debt
- -
- -
- -
10
9
7
19
18
Total Equity
59
64
-73
74
34
336
484
511
Return on Invested Capital (%)
- -
7.23
- -
- -
- -
- -
13.36
11.82
Return on Capital (%)
- -
9.43
-1,499.08
- -
- -
- -
18.45
15.84
Return on Common Equity (%)
- -
-15.24
133.73
87.01
-150.08
-152.88
19.1
16.44

Capital Structure

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
4
4
5
LT Borrowings
- -
- -
- -
LT Finance Leases
18
19
18
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
244
249
249
Market Capitalization
4,530
4,482
3,437

Working Capital

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
668
576
541
Cash, Cash Equivalents & STI
526
437
429
Accounts Receivable, Net
104
105
73
Inventories
9
8
8
Total Current Liabilities
317
370
350
Payables & Accruals
74
87
91
ST Debt
4
4
5
Deferred Revenue
240
278
255

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
91.39%
44.13%
Free Cash Flow
- -
133.53%
31.88%
Net Income, GAAP
- -
231.67%
-127.68%
Sales/Revenue/Turnover
- -
19.67%
18.56%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
90
96
107
109
401
2025
108
113
126
129
476
2026
128
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.36
-0.12
-0.99
0.08
-1.35
2025
0.07
0.08
0.08
0.09
0.32
2026
0.04
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Shiv Ramji
Full Time Employees
1,285
Sector
Technology
Industry
Software - Infrastructure
Address
94 Shlomo Shmelzer Road Petah Tikva HM Israel 4970602
IPO Date
Nov 6, 2020
Business
Cellebrite DI Ltd. Cellebrite DI Ltd. (Nasdaq:CLBT), founded in 1999 and headquartered in Petah Tikva, Israel, provides digital intelligence solutions for legally sanctioned investigations to law enforcement, intelligence agencies, military branches, enterprises, and corporations worldwide; operates across Europe, the Middle East, Africa, the Americas, and Asia-Pacific; offers a comprehensive Digital Intelligence platform including the flagship Cellebrite UFED for mobile device data extraction from over 30,000 devices, Pathfinder for advanced investigations and data analytics, Guardian SaaS suite for case management with new EU data-residency region and expanded Android/iOS collection via Inseyets, solutions for cloud data, social media, computers, drones, and open-source intelligence; provides training services, cybersecurity, and incident response capabilities. Cellebrite's core offerings encompass forensic extraction, review, analysis, decoding, decryption, sharing, and management of digital evidence across the investigative lifecycle for cases including child exploitation, homicide, terrorism, organized crime, human trafficking, corporate security, cryptocurrency investigations, and intellectual property theft. The company recently agreed to acquire Corellium, a developer of Arm-based virtualization software for mobile vulnerability research, DevSecOps, and virtual device testing, in a $170 million cash deal plus up to $30 million contingent consideration, expected to close in 2025; acquired Cyber Technology Services (CyTech) in 2024 to bolster U.S. federal capabilities through newly formed Cellebrite Federal Solutions with FedRAMP High pursuit and U.S. Department of Justice sponsorship; launched Autumn 2025 product releases featuring Guardian Investigate (limited production with general availability in early 2026), AWS GovCloud deployment for Pathfinder, expanded NCMEC CyberTipline integration in Inseyets for faster CSAM matching, and Corellium tooling subscriptions by defense customers in EMEA and APAC; appointed permanent CEO Thomas Hogan following interim leadership and Yossi Carmil's retirement. Cellebrite remains majority-owned by Japan-based Sun Corporation, employs over 1,100 people, and reports subscription revenue growth of 21% year-over-year in recent quarters with recurring revenue forming the bulk of its business.

Company News

  • Kaplan Fox is Investigating Cellebrite DI Ltd. (CLBT) for Potential Violations of the Federal Securities Laws

  • Cellebrite: Mobile Forensics Leadership At A Compelling Valuation

  • Cellebrite Federal Solutions, Inc. (CFSI) répond à la norme avancée de cybersécurité du ministère américain de la Défense, renforçant ainsi son engagement en faveur de la sécurité des opérations fédérales

  • Cellebrite Guardian completa la evaluación IRAP: obtiene la certificación PROTECTED

  • Cellebrite Guardian Completes IRAP Assessment: Achieves PROTECTED Level for Australian Government Agencies

  • CFSI obtiene el Estándar Avanzado de Ciberseguridad del Departamento de Guerra de EE.UU.

  • Cellebrite Federal Solutions, Inc. (CFSI) Achieves U.S. Department of War's Advanced Cybersecurity Standard, Reinforcing Commitment to Secure Federal Operations

  • Kaplan Fox & Kilsheimer LLP is Investigating Cellebrite DI Ltd. (CLBT) for Possible Securities Law Violations

  • Cellebrite DI Ltd. (NASDAQ:CLBT) Given Consensus Rating of “Moderate Buy” by Brokerages

  • Kaplan Fox Reminds Cellebrite DI Ltd. (CLBT) Investors of an Investigation into Potential Securities Law Violations

  • Cellebrite stellt den Streitkräften mit der Einführung des «Portable Tactical Extraction Kit» (C-TEK) Informationen aus dem Einsatzgebiet zur Verfügung

  • Cellebrite met ses capacités de renseignement sur le champ de bataille au service des forces armées avec le lancement du Portable Tactical Extraction Kit (C-TEK)

  • Kaplan Fox & Kilsheimer LLP Alerts Investors of Cellebrite DI Ltd. (CLBT) to an Investigation of Potential Securities Law Violations

  • Cellebrite Brings Battlefield Intelligence to the Armed Forces with Launch of Portable Tactical Extraction Kit (C-TEK)

  • Bank of America Corp DE Reduces Position in Cellebrite DI Ltd. $CLBT

  • Kaplan Fox Notifies Cellebrite DI Ltd. (CLBT) Investors of a Securities Investigation into the Company

  • Cellebrite Investigated for Securities Fraud by Block & Leviton; CLBT Investors Should Contact the Firm to Possibly Recover Losses

  • Kaplan Fox is Investigating Cellebrite DI Ltd. (CLBT) on Behalf of Investors for Potential Securities Law Violations

  • Cellebrite DI Ltd. (CLBT) Securities Investigation Notice - Levi & Korsinsky

  • Cellebrite DI Ltd. (CLBT) Securities Investigation Notice - Levi & Korsinsky